Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GIM-407
- Development stage
- Phase 1
- Lead developer
- Georgiamune
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
GIM-407 is a first-in-class, orally administered small molecule drug developed as a selective activator of regulatory T cells (Tregs). Regulatory T cells are critical for maintaining immune self-tolerance and preventing autoimmune diseases. By enhancing both the quantity and function of Tregs, GIM-407 aims to restore immune balance in patients with autoimmune disorders. The drug is currently in Phase 1 clinical trials, initially being tested in healthy volunteers to evaluate its safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and biomarker activity. The results from these studies will inform the selection of specific autoimmune diseases for future clinical development.
Beyond the preview
Go deeper on GIM-407.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GIM-407.